Latest Conference Coverage

Natalizumab Improves Social and Mental Health in Patients with Multiple Sclerosis

Researchers compared Neuro-QoL scores between patients treated with natalizumab and ocrelizumab, another high-efficacy treatment for MS.

The Long-Term Efficacy of Inebilizumab in NMOSD: Bruce Cree, MD, PhD, MAS

The clinical research director at the UCSF Multiple Sclerosis Center discussed the findings of the long-term open-label assessment of inebilizumab in neuromyelitis optica spectrum disorder.

Fenfluramine Improves Executive Function in Lennox-Gastaut Syndrome

Improvement was statistically significant for Cognition and the Global Executive Composite score, where approximately twice as many patients achieved clinically meaningful improvement.

Stroke Common Cause of Seizures, Inebilizumab Demonstrates Continued Benefits, Fremanezumab Safe in Patients With CV Risk

Advantages of Fremanezumab Among CGRP Migraine Agents: Stephanie J. Nahas, MD

The associate professor and director of the Headache Medicine Fellowship Program at Thomas Jefferson University detailed the reasons fremanezumab stands out among a crowded migraine treatment landscape.

Nipocalimab Shows Promise as Myasthenia Gravis Treatment: Jeffrey Guptill, MD, MS, MHS

The associate professor of neurology and neurologist at Duke University discussed the positive results of nipocalimab, a monoclonal antibody, in patients with myasthenia gravis.

Novel Mobile Toolbox Battery Could Improve Cognitive Impairment Detection

The MTB is built to safely, remotely, and effectively collect data from assessments that measure the executive function, language, memory, and processing speed of adults, and can be captured via smartphone.

IMU-838 Efficacious and Well-Tolerated in Relapsing Multiple Sclerosis

The therapy has fewer off-target effects on kinases and may be better-tolerated than other DHODH inhibitors for patients with relapsing MS.

Aspirin Holds Potential for Stroke Prevention in Cerebral Amyloid Angiopathy

The findings add to the body of evidence for use of antiplatelets in patients with cerebral amyloid angiopathy.

Atogepant Continues to Shine in Phase 3 ADVANCE Study: Lawrence Severt, MD, PhD

The director at AbbVie discussed a number of abstracts presented at AAN 2021 involving atogepant and its phase 3 ADVANCE study.

Retrospective Database Characterizes Causes, Types of Post-Stroke Seizures

Lower-Sodium Oxybate Has Similar Efficacy, Easily Transitions From Higher-Sodium Oxybate

Researchers saw the least amount of adverse events and the least time to stable dose in participants entering the study with SXB treatment.

Telestroke Accurately Distinguishes Ischemic Stroke From Stroke Mimics

Researchers from the University of Utah analyzed the use of their telestroke system with 27 outside “stroke” facilities.

Applications of Telestroke and Teleneurology: Jason Poon, MD

The neurologist at University of Utah discussed his research presented at AAN 2021 on telestroke’s accuracy of differentiating between acute ischemic stroke and mimics.

Inebilizumab Has Enduring Effect as NMOSD Treatment

Patients in the randomized controlled trial and the open-label extension treated with inebilizumab experienced similar rates of being attack-free, extending as far as 4 years.

Ublituximab and the Anti-CD20 Class in Multiple Sclerosis: Lawrence Steinman, MD

The professor of neurology and Neurological Sciences, Pediatrics, and Genetics at Stanford Medicine discussed the ULTIMATE trial data presented at the 2021 AAN Annual Meeting.

NeuroVoices: Joseph Sirven, MD, on Expanding Research on Social Determinants of Health in Epilepsy

The professor of neurology at Mayo Clinic discussed the need for understanding more about how social determinants of health can impact epilepsy treatment delays.

Pimavanserin vs Off-Label Psychotics for Dementia-Related Psychosis: Clive Ballard, MD

The dean at the University of Exeter Medical School discussed the questions related to treating dementia-related psychosis and the options available.

Treatment Compliance Higher Among Ofatumumab-Treated Patients Than Teriflunomide

Patient/guardian decision, adverse event, and physician decision were the 3 noted reasons for discontinuation with either ofatumumab or teriflunomide.

Stem Cell Therapy for Spinal Cord Injury on Pace to Soon Enter Human Phase Testing

In an AAN plenary talk, Mark H. Tuszynski, MD, PhD, detailed the work he and colleagues have done to push stem cell therapy from the lab to the clinic to improve care for spinal cord injury.

African American Women Experience Greatest Disadvantage in Post-Stroke Rehabilitation

Researchers analyzed disparities in stroke rehab and found that women and African Americans had the lowest functional performance.

Trends in Movement Disorder Research: Ihtsham ul Haq, MD, FAAN

The chief of Movement Disorders Division at the University of Miami Miller School of Medicine discussed some of the recent focused efforts to uncover more about Parkinson disease and what is on the horizon.

Fremanezumab Demonstrates Efficacy and Safety in Pair of AAN Posters

Patients with a previous history of cardiovascular risks experienced similarly low number of cardiovascular events with treatment of fremanezumab compared with placebo.

Validated MANAGE-PD Tool May Identify Parkinson Disease Treatment Gaps

In total, 50% of patients eligible for device-aided therapies did not report having any discussion with providers about future device-aided therapies.

Treatment Disparities, Neurologic Complications Clarified by COVID-19 Neurological Research

The 2021 AAN Meeting Hot Topics plenary focused on neurological facets of COVID-19, and featured insight from Anthony Fauci, MD, of NIAID, and Walter Koroshetz, MD, of NINDS, among others.

Mitigating Disparities in Stroke Rehabilitation Care: Sana Somani, MD, MBBS

The vascular neurology fellow at the University of Maryland Medical Center discussed strategies to improve stroke care efficiency in women and African Americans.

Deep Brain Stimulation Leads Advances in Neuromodulation for Movement Disorders

An AAN session included presentations of research on the latest advancements and knowledge in neuromodulation for patients with these disorders.

Efficacy and Safety of Fremanezumab Further Displayed: Stephanie J. Nahas, MD

The associate professor and director of the Headache Medicine Fellowship Program at Thomas Jefferson University discussed 2 research projects she led presented at AAN 2021 on the efficacy and safety of fremanezumab.

Implementing Patient-Specific Stroke Discharge Instructions: Marian LaMonte, MD, MSN, FAAN

The chief of neurology at Ascension Saint Agnes discussed how providing an overview of patient-specific risk factors and mitigation can improve poststroke care.

Aducanumab EMBARK Trial Seeks to Characterize Treatment Durability, Effects of Interruption

Aducanumab currently sits before the FDA for review for the treatment of Alzheimer disease, with a PDUFA date set for June 7, 2021.